models that simulate biological processes and support the design of drug candidates across multiple disease areas.

Its platform integrates predictive and generative AI systems to explore chemical space, identify therapeutic targets, and propose new molecular structures with potential medical applications. It collaborates with pharmaceutical companies on research programs in areas such as oncology and immunology, with the aim of accelerating early-stage drug discovery and improving candidate selection.

The organization also develops internal pipelines of AI-designed drug candidates and is progressing toward clinical testing of its first programs. Its work combines computational biology, medicinal chemistry, and machine learning to support end-to-end drug design workflows, from target identification to preclinical evaluation.